Bisphosphonates modulate vital functions of human osteoblasts and affect their interactions with breast cancer cells

Breast Cancer Research and Treatment

Volumn 140, Issue 1, 2013, Pages 35-48

  Kaiser, Tatjana ^a,b   Teufel, Ingrid ^a   Geiger, Konstanze ^b   Vater, Yvonne ^b   Aicher, Wilhelm K ^b   Klein, Gerd ^b   Fehm, Tanja ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Bisphosphonates; Bone marrow microenvironment; Bone metastases; Breast cancer; CCL2 MCP 1; Osteoblasts

Indexed keywords

ALKALINE PHOSPHATASE; BONE SIALOPROTEIN; CARBOXY TERMINAL TELOPEPTIDE; CASPASE; COLLAGEN; COLLAGEN TYPE 1 ALPHA2; IBANDRONIC ACID; MEVALONIC ACID; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOCALCIN; OSTEONECTIN; PAMIDRONIC ACID; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

APOPTOSIS; ARTICLE; BONE DEVELOPMENT; BREAST CANCER; CELL ADHESION; CELL DIFFERENTIATION; CELL FUNCTION; CELL INTERACTION; CELL METABOLISM; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG MECHANISM; EXTRACELLULAR MATRIX; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MARKER GENE; OSTEOBLAST; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

APOPTOSIS; BREAST NEOPLASMS; CASPASES; CELL ADHESION; CELL DIFFERENTIATION; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CHEMOKINE CCL2; CHEMOKINES; DIPHOSPHONATES; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION REGULATION; GENETIC MARKERS; HUMANS; IMIDAZOLES; OSTEOBLASTS;

EID: 84880253201     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2613-z     Document Type: Article

References (49)

1. Chiang AC, Massague J (2008) Molecular basis of metastasis. N Engl J Med 359(26):2814-2823
2. Guise TA, Brufsky A, Coleman RE (2010) Understanding and optimizing bone health in breast cancer. Curr Med Res Opin 26:3-20
3. Gnant M, Hadji P (2010) Prevention of bone metastases and management of bone health in early breast cancer. Breast Cancer Res 12(6):216
4. Kakonen SM, Mundy GR (2003) Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer 97(3 Suppl):834-839 (Pubitemid 36125820)
5. Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, Reitsma DJ, Heffernan M, Seaman JJ (2000) Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 88(5):1082-1090 (Pubitemid 30127670)
6. Body JJ, Bartl R, Burckhardt P, Delmas PD, Diel IJ, Fleisch H, Kanis JA, Kyle RA, Mundy GR, Paterson AH, et al. (1998) Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol 16(12):3890-3899 (Pubitemid 29001543)
7. Mundy GR, Yoneda T (1998) Bisphosphonates as anticancer drugs. N Engl J Med 339(6):398-400 (Pubitemid 28363805)
8. Russell RG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19(6):733-759
9. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13(4):581-589 (Pubitemid 28163009)
10. Sahni M, Guenther HL, Fleisch H, Collin P, Martin TJ (1993) Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 91(5):2004-2011 (Pubitemid 23141472)
11. Vitte C, Fleisch H, Guenther HL (1996) Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology 137(6):2324-2333 (Pubitemid 26155765)
12. Fromigue O, Body JJ (2002) Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts. J Endocrinol Invest 25(6):539-546 (Pubitemid 34661843)
13. Xiong Y, Yang HJ, Feng J, Shi ZL, Wu LD (2009) Effects of alendronate on the proliferation and osteogenic differentiation of MG-63 cells. J Int Med Res 37(2):407-416
14. Corrado A, Neve A, Maruotti N, Gaudio A, Marucci A, Cantatore FP (2010) Dose-dependent metabolic effect of zoledronate on primary human osteoblastic cell cultures. Clin Exp Rheumatol 28(6):873-879
15. Viereck V, Emons G, Lauck V, Frosch KH, Blaschke S, Grundker C, Hofbauer LC (2002) Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 291(3):680-686 (Pubitemid 34687400)
16. Frediani B, Spreafico A, Capperucci C, Chellini F, Gambera D, Ferrata P, Baldi F, Falsetti P, Santucci A, Bocchi L, et al. (2004) Long-term effects of neridronate on human osteoblastic cell cultures. Bone 35(4):859-869 (Pubitemid 39349217)
17. Pan B, To LB, Farrugia AN, Findlay DM, Green J, Gronthos S, Evdokiou A, Lynch K, Atkins GJ, Zannettino AC (2004) The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cells in vitro. Bone 34(1):112-123 (Pubitemid 38142439)
18. Recker RR, Delmas PD, Halse J, Reid IR, Boonen S, Garcia-Hernandez PA, Supronik J, Lewiecki EM, Ochoa L, Miller P, et al. (2008) Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res 23(1):6-16
19. Garcia-Moreno C, Serrano S, Nacher M, Farre M, Diez A, Marinoso ML, Carbonell J, Mellibovsky L, Nogues X, Ballester J, et al. (1998) Effect of alendronate on cultured normal human osteoblasts. Bone 22(3):233-239 (Pubitemid 28127478)
20. Greiner S, Kadow-Romacker A, Lubberstedt M, Schmidmaier G, Wildemann B (2007) The effect of zoledronic acid incorporated in a poly(D,L-lactide) implant coating on osteoblasts in vitro. J Biomed Mater Res A 80(4):769-775
21. Reinholz GG, Getz B, Pederson L, Sanders ES, Subramaniam M, Ingle JN, Spelsberg TC (2000) Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res 60(21):6001-6007
22. Senaratne SG, Colston KW (2002) Direct effects of bisphosphonates on breast cancer cells. Breast Cancer Res 4(1):18-23 (Pubitemid 34097552)
23. Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, Delmas P, Delaisse JM, Clezardin P (2000) Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 60(11):2949-2954 (Pubitemid 30395820)
24. Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW (2000) Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 82(8):1459-1468 (Pubitemid 30175914)
25. Rachner TD, Singh SK, Schoppet M, Benad P, Bornhäuser M, Ellenrieder V, Ebert R, Jakob F, Hofbauer LC (2010) Zoledronic acid induces apoptosis and changes the TRAIL/OPG ratio in breast cancer cells. Cancer Lett 287(1):109-116
26. Dedes PG, Gialeli C, Tsonis AI, Kanakis I, Theocharis AD, Kletsas D, Tzanakakis GN, Karamanos NK (2012) Expression of matrix macromolecules and functional properties of breast cancer cells are modulated by the bisphosphonate zoledronic acid. Biochim Biophys Acta 1820(12):1926-1939
27. Coleman RE, Lipton A, Roodman GD, Guise TA, Boyce BF, Brufsky AM, Clezardin P, Croucher PI, Gralow JR, Hadji P, et al. (2010) Metastasis and bone loss: advancing treatment and prevention. Cancer Treat Rev 36(8):615-620
28. Burger JA, Kipps TJ (2006) CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 107(5):1761-1767 (Pubitemid 43289351)
29. Roodman DG (2003) Role of stromal-derived cytokines and growth factors in bone metastasis. Cancer 97(3 Suppl):733-738
30. Gillies RJ, Didier N, Denton M (1986) Determination of cell number in monolayer cultures. Anal Biochem 159(1):109-113 (Pubitemid 17228232)
31. Dieterle A, Orth R, Daubrawa M, Grotemeier A, Alers S, Ullrich S, Lammers R, Wesselborg S, Stork B (2009) The Akt inhibitor triciribine sensitizes prostate carcinoma cells to TRAIL-induced apoptosis. Int J Cancer 125(4):932-941
32. Masuda T, Deng X, Tamai R (2009) Mouse macrophages primed with alendronate down-regulate monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1alpha (MIP-1alpha) production in response to Toll-like receptor (TLR) 2 and TLR4 agonist via Smad3 activation. Int Immunopharmacol 9(9):1115-1121
33. Schüler Y, Lee-Thedieck C, Geiger K, Kaiser T, Ino Y, Aicher WK, Klein G (2012) Osteoblast-secreted factors enhance the expression of dysadherin and CCL2-dependent migration of renal carcinoma cells. Int J Cancer 130(2):288-299
34. Benford HL, McGowan NW, Helfrich MH, Nuttall ME, Rogers MJ (2001) Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone 28(5):465-473 (Pubitemid 32409997)
35. Coleman ML, Olson MF (2002) Rho GTPase signalling pathways in the morphological changes associated with apoptosis. Cell Death Differ 9(5):493-504 (Pubitemid 34521177)
36. Conti P, DiGioacchino M (2001) MCP-1 and RANTES are mediators of acute and chronic inflammation. Allergy Asthma Proc 22(3):133-137
37. Molloy AP, Martin FT, Dwyer RM, Griffin TP, Murphy M, Barry FP, O'Brien T, Kerin MJ (2009) Mesenchymal stem cell secretion of chemokines during differentiation into osteoblasts, and their potential role in mediating interactions with breast cancer cells. Int J Cancer 124(2):326-332
38. Li X, Qin L, Bergenstock M, Bevelock LM, Novack DV, Partridge NC (2007) Parathyroid hormone stimulates osteoblastic expression of MCP-1 to recruit and increase the fusion of pre/osteoclasts. J Biol Chem 282(45):33098-33106 (Pubitemid 350159306)
39. Loberg RD, Day LL, Harwood J, Ying C, St John LN, Giles R, Neeley CK, Pienta KJ (2006) CCL2 is a potent regulator of prostate cancer cell migration and proliferation. Neoplasia 8(7):578-586 (Pubitemid 44061313)
40. Lu Y, Cai Z, Galson DL, Xiao G, Liu Y, George DE, Melhem MF, Yao Z, Zhang J (2006) Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate 66(12):1311-1318 (Pubitemid 44384308)
41. Loberg RD, Tantivejkul K, Craig M, Neeley CK, Pienta KJ (2007) PAR1-mediated RhoA activation facilitates CCL2-induced chemotaxis in PC-3 cells. J Cell Biochem 101(5):1292-1300 (Pubitemid 47253727)
42. Kinder M, Chislock E, Bussard KM, Shuman L, Mastro AM (2008) Metastatic breast cancer induces an osteoblast inflammatory response. Exp Cell Res 314(1):173-183 (Pubitemid 350182446)
43. Zhu J, Jia X, Xiao G, Kang Y, Partridge NC, Qin L (2007) EGF-like ligands stimulate osteoclastogenesis by regulating expression of osteoclast regulatory factors by osteoblasts: implications for osteolytic bone metastases. J Biol Chem 282(37):26656-26664 (Pubitemid 47501956)
44. Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, Kaiser EA, Snyder LA, Pollard JW (2011) CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475(7355):222-225
45. Festuccia C, Bologna M, Gravina GL, Guerra F, Angelucci A, Villanova I, Millimaggi D, Teti A (1999) Osteoblast conditioned media contain TGF-beta1 and modulate the migration of prostate tumor cells and their interactions with extracellular matrix components. Int J Cancer 81(3):395-403 (Pubitemid 29165198)
46. Gallo M, De Luca A, Lamura L, Normanno N (2012) Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancer. Ann Oncol 23(3):597-604
47. Walter M, Liang S, Ghosh S, Hornsby PJ, Li R (2009) Interleukin 6 secreted from adipose stromal cells promotes migration and invasion of breast cancer cells. Oncogene 28(30):2745-2755
48. Knerr K, Ackermann K, Neidhart T, Pyerin W (2004) Bone metastasis: osteoblasts affect growth and adhesion regulons in prostate tumor cells and provoke osteomimicry. Int J Cancer 111(1):152-159 (Pubitemid 38859297)
49. Nam JS, Kang MJ, Suchar AM, Shimamura T, Kohn EA, Michalowska AM, Jordan VC, Hirohashi S, Wakefield LM (2006) Chemokine (C-C motif) ligand 2 mediates the prometastatic effect of dysadherin in human breast cancer cells. Cancer Res 66(14):7176-7184 (Pubitemid 44197696)